| | | | | Short-term intravenous interferon therapy for chronic hepatitis B | | | Hiroaki Okushin;Toru Ohnishi;Kazuhiko Morii;Koichi Uesaka;Shiro Yuasa | | | AIM:To investigate the therapeutic efficacy of short- term, multiple daily dosing of intravenous interferon (IFN) in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. METHODS:IFN-β was intravenously administered at a total dose of 102 million international units (MIU) over a period of 28 d in 26 patients positive for HBeAg and HBV-DNA. IFN-beta was administered at doses of 2 MIU and 1 MIU on d 1, 3 MIU twice daily from d 2 to d 7, and 1 MIU thrice daily from d 8 to d 28. Patients were followed up for 24 wk after the end of treatment. RESULTS:Six months after the end of the treatment, loss of HBV-DNA occurred in 13 (50.0%) of the 26 patients, loss of HBeAg in 9 (34.6%), development of anti-HBe in 10 (38.5%), HBeAg seroconversion in 8 (30.8%), and normalization of alanine aminotransferase (ALT) levels in 11 (42.0%). CONCLUSION:This 4-wk long IFN-β therapy, which was much shorter than conventional therapy lasting 12 wk or even more than 1 year, produced therapeutic effects similar to those achieved by IFN-α or pegylated- IFN-α (peg-IFN). Fewer adverse effects, greater efficacy, and a shorter treatment period led to an improvement in patients’ quality of life. IFN-β is administered intravenously, whereas IFN-α is administered intramuscularly or subcutaneously. Because both interferons are known to bind to an identical receptor and exert antiviral effects through intracellular signal transduction, the excellent results of IFN-β found in this study may be attributed to the multiple doses allowed by the intravenous route.
【作者单位】：Department of Internal Medicine Himeji Red Cross Hospital;Department of Internal Medicine;Himeji Red Cross Hospital;Department of Internal Medicine;Himeji Red Cross Hospital;Department of Internal Medicine;Himeji Red Cross Hospital;Department of Internal Medicine;Himeji Red Cross Hospital;Hyogo;Japan;Hyogo;Japan;Hyogo;Japan;Hyogo;Japan;Hyogo;Japan
【分类号】：R512.62
【DOI】：CNKI:SUN:ZXXY.0.2008-19-014
【正文快照】：
INTRODUCTION The increasing prevalence of chronic hepatitis caused by hepatitis B or C virus infection represents a concern in many regions worldwide. Interferons (IFN) are widely used in the treatment of the disease. With the recent launch of lamivudine,… | | |
| | |  推荐 CAJ下载  PDF下载 | | | CAJViewer7.0阅读器支持所有CNKI文件格式，AdobeReader仅支持PDF格式 | | | | Short-term intravenous interferon therapy for chronic hepatitis B | | | Hiroaki Okushin;Toru Ohnishi;Kazuhiko Morii;Koichi Uesaka;Shiro Yuasa;Department of Internal Medicine;Himeji Red Cross Hospital;Hyogo;Japan | | | AIM:To investigate the therapeutic efficacy of short- term, multiple daily dosing of intravenous interferon (IFN) in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. METHODS:IFN-β was intravenously administered at a total dose of 102 million international units (MIU) over a period of 28 d in 26 patients positive for HBeAg and HBV-DNA. IFN-beta was administered at doses of 2 MIU and 1 MIU on d 1, 3 MIU twice daily from d 2 to d 7, and 1 MIU thrice daily from d 8 to d 28. Patients were followed up for 24 wk after the end of treatment. RESULTS:Six months after the end of the treatment, loss of HBV-DNA occurred in 13 (50.0%) of the 26 patients, loss of HBeAg in 9 (34.6%), development of anti-HBe in 10 (38.5%), HBeAg seroconversion in 8 (30.8%), and normalization of alanine aminotransferase (ALT) levels in 11 (42.0%). CONCLUSION:This 4-wk long IFN-β therapy, which was much shorter than conventional therapy lasting 12 wk or even more than 1 year, produced therapeutic effects similar to those achieved by IFN-α or pegylated- IFN-α (peg-IFN). Fewer adverse effects, greater efficacy, and a shorter treatment period led to an improvement in patients’ quality of life. IFN-β is administered intravenously, whereas IFN-α is administered intramuscularly or subcutaneously. Because both interferons are known to bind to an identical receptor and exert antiviral effects through intracellular signal transduction, the excellent results of IFN-β found in this study may be attributed to the multiple doses allowed by the intravenous route.
【Keyword】：Chronic hepatitis B;Hepatitis B e antigen;Hepatitis B virus;Interferon beta;Multiple daily dosing;Short-term treatment;Intravenous injection |
| | | | | | 1 | Honkoop P, ,Niesters HG, de Man RA, Osterhaus AD, Schalm SW; Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. [M];J Hepatol; 1997年 | | 2 | Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L,Edmundson S, Lai CL; Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B [M];Gastroenterology; 2000年 |
|
|
|